These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

212 related items for PubMed ID: 15274072

  • 1. Adapting the Lung Cancer Symptom Scale (LCSS) to mesothelioma: using the LCSS-Meso conceptual model for validation.
    Hollen PJ, Gralla RJ, Liepa AM, Symanowski JT, Rusthoven JJ.
    Cancer; 2004 Aug 01; 101(3):587-95. PubMed ID: 15274072
    [Abstract] [Full Text] [Related]

  • 2. Measuring quality of life in patients with pleural mesothelioma using a modified version of the Lung Cancer Symptom Scale (LCSS): psychometric properties of the LCSS-Meso.
    Hollen PJ, Gralla RJ, Liepa AM, Symanowski JT, Rusthoven JJ.
    Support Care Cancer; 2006 Jan 01; 14(1):11-21. PubMed ID: 15999264
    [Abstract] [Full Text] [Related]

  • 3. Pemetrexed in malignant pleural mesothelioma.
    Hazarika M, White RM, Booth BP, Wang YC, Ham DY, Liang CY, Rahman A, Gobburu JV, Li N, Sridhara R, Morse DE, Lostritto R, Garvey P, Johnson JR, Pazdur R.
    Clin Cancer Res; 2005 Feb 01; 11(3):982-92. PubMed ID: 15709163
    [Abstract] [Full Text] [Related]

  • 4. Pemetrexed and cisplatin for malignant pleural mesothelioma: a new standard of care?
    Rusch VW.
    J Clin Oncol; 2003 Jul 15; 21(14):2629-30. PubMed ID: 12860935
    [No Abstract] [Full Text] [Related]

  • 5. [Chemotherapy of malignant pleural mesothelioma: have we made any progress?].
    Reck M, Heigener DF, Gatzemeier U.
    Zentralbl Chir; 2008 Jun 15; 133(3):238-42. PubMed ID: 18563688
    [Abstract] [Full Text] [Related]

  • 6. Single-arm, open label study of pemetrexed plus cisplatin in chemotherapy naïve patients with malignant pleural mesothelioma: outcomes of an expanded access program.
    Obasaju CK, Ye Z, Wozniak AJ, Belani CP, Keohan ML, Ross HJ, Polikoff JA, Mintzer DM, Monberg MJ, Jänne PA, Pemetrexed Expanded Access Program Investigators.
    Lung Cancer; 2007 Feb 15; 55(2):187-94. PubMed ID: 17092602
    [Abstract] [Full Text] [Related]

  • 7. Pemetrexed-cisplatin combination in mesothelioma.
    Reck M, Gatzemeier U.
    Expert Rev Anticancer Ther; 2005 Apr 15; 5(2):231-7. PubMed ID: 15877521
    [Abstract] [Full Text] [Related]

  • 8. Pemetrexed alone or in combination with cisplatin in previously treated malignant pleural mesothelioma: outcomes from a phase IIIB expanded access program.
    Jänne PA, Wozniak AJ, Belani CP, Keohan ML, Ross HJ, Polikoff JA, Mintzer DM, Ye Z, Monberg MJ, Obasaju CK, Pemetrexed expanded access program investigators.
    J Thorac Oncol; 2006 Jul 15; 1(6):506-12. PubMed ID: 17409909
    [Abstract] [Full Text] [Related]

  • 9. Symptoms and patient-reported well-being: do they predict survival in malignant pleural mesothelioma? A prognostic factor analysis of EORTC-NCIC 08983: randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma.
    Bottomley A, Coens C, Efficace F, Gaafar R, Manegold C, Burgers S, Vincent M, Legrand C, van Meerbeeck JP, EORTC-NCIC.
    J Clin Oncol; 2007 Dec 20; 25(36):5770-6. PubMed ID: 18089874
    [Abstract] [Full Text] [Related]

  • 10. Pemetrexed: new drug. Pleural mesothelioma: a first encouraging trial.
    Prescrire Int; 2005 Dec 20; 14(80):212-4. PubMed ID: 16400741
    [Abstract] [Full Text] [Related]

  • 11. Carboplatin and pemetrexed in the management of malignant pleural mesothelioma: a realistic treatment option?
    Li L, Razak AR, Hughes A.
    Lung Cancer; 2009 May 20; 64(2):207-10. PubMed ID: 18926592
    [Abstract] [Full Text] [Related]

  • 12. Clinical impact of extrapleural pneumonectomy for malignant pleural mesothelioma.
    Ambrogi V, Baldi A, Schillaci O, Mineo TC.
    Ann Surg Oncol; 2012 May 20; 19(5):1692-9. PubMed ID: 22193885
    [Abstract] [Full Text] [Related]

  • 13. [Prognosis related clinical and molecular factors in malignant pleural mesothelioma].
    Wang YY, Zhang H, Bai H, Wang SH, Wu MN, An TT, Zhao J, Zhuo ML, Duan JC, Wang ZJ, Wang J.
    Zhonghua Jie He He Hu Xi Za Zhi; 2013 Mar 20; 36(3):162-8. PubMed ID: 23856136
    [Abstract] [Full Text] [Related]

  • 14. Phase II study of a liposome-entrapped cisplatin analog (L-NDDP) administered intrapleurally and pathologic response rates in patients with malignant pleural mesothelioma.
    Lu C, Perez-Soler R, Piperdi B, Walsh GL, Swisher SG, Smythe WR, Shin HJ, Ro JY, Feng L, Truong M, Yalamanchili A, Lopez-Berestein G, Hong WK, Khokhar AR, Shin DM.
    J Clin Oncol; 2005 May 20; 23(15):3495-501. PubMed ID: 15908659
    [Abstract] [Full Text] [Related]

  • 15. Short-term treatment-related symptoms and quality of life: results from an international randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an EORTC Lung-Cancer Group and National Cancer Institute, Canada, Intergroup Study.
    Bottomley A, Gaafar R, Manegold C, Burgers S, Coens C, Legrand C, Vincent M, Giaccone G, Van Meerbeeck J, EORTC Lung-Cancer Group, National Cancer Institute, Canada.
    J Clin Oncol; 2006 Mar 20; 24(9):1435-42. PubMed ID: 16446322
    [Abstract] [Full Text] [Related]

  • 16. Pemetrexed (Alimta): improving outcomes in malignant pleural mesothelioma.
    Budde LS, Hanna NH.
    Expert Rev Anticancer Ther; 2004 Jun 20; 4(3):361-8. PubMed ID: 15161435
    [Abstract] [Full Text] [Related]

  • 17. Assessment of change of quality of life in terminally ill patients under cancer pain management using the EORTC Core Quality of Life Questionnaire (QLQ-C30) in a Korean sample.
    Park KU.
    Oncology; 2008 Jun 20; 74 Suppl 1():7-12. PubMed ID: 18758191
    [Abstract] [Full Text] [Related]

  • 18. Nursing considerations for administering pemetrexed (Alimta) in combination with cisplatin for malignant pleural mesothelioma.
    Orbaugh KK.
    Clin J Oncol Nurs; 2004 Jun 20; 8(3):242-7. PubMed ID: 15208818
    [Abstract] [Full Text] [Related]

  • 19. Efficacy and safety of pemetrexed in combination with cisplatin for malignant pleural mesothelioma: a phase I/II study in Japanese patients.
    Nakagawa K, Yamazaki K, Kunitoh H, Hida T, Gemba K, Shinkai T, Ichinose Y, Adachi S, Nambu Y, Saijo N, Fukuoka M.
    Jpn J Clin Oncol; 2008 May 20; 38(5):339-46. PubMed ID: 18434338
    [Abstract] [Full Text] [Related]

  • 20. Safety and effectiveness of pemetrexed in patients with malignant pleural mesothelioma based on all-case drug-registry study.
    Kuribayashi K, Voss S, Nishiuma S, Arakawa K, Nogi Y, Mikami K, Kudoh S.
    Lung Cancer; 2012 Mar 20; 75(3):353-9. PubMed ID: 21890228
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.